September 25, 2020
Tony Hagen
Debra Patt, MD, PhD, MBA, discusses issues affecting biosimilar uptake at the Patient-Centered Oncology Care® 2020 virtual conference.
September 24, 2020
Skylar Jeremias
The NOR-SWITCH study showed comparable safety, efficacy, and immunogenicity for patients with inflammatory bowel disease (IBD) who switched from reference infliximab to Celltrion biosimilar (CT-P13).
September 21, 2020
Breast cancer specialist Hope S. Rugo, MD, FASCO, an advisory board member for The Center for Biosimilars®, has been at the forefront of groundbreaking oncology advancements.
September 19, 2020
Isha Bangia, PharmD, MBA
Amgen's Onpro autoinjector device for pegfilgrastim is a stunning example of how product differentiation via drug delivery devices can protect market share in the biologics market.
September 8, 2020
Deana Ferreri, PhD
The random jumble of letters that the FDA attaches to new biologics and biosimilars plays a big role in patient acceptance of these drugs, investigators report.
September 7, 2020
This summer, The Center for Biosimilars® interviewed several experts for their opinions on the current need for biosimilars and how companies are working to overcome barriers to uptake. Here are some highlights.
September 3, 2020
Multiple studies indicate the nocebo effect is particularly influential in the treatment of inflammatory bowel disease (IBD), according to an opinion piece.
Bio-Thera said it has begun testing the safety its ustekinumab biosimilar in healthy volunteers.
September 1, 2020
A look at efforts biosimilar manufacturers are taking to develop treatments for coronavirus disease 2019 (COVID-19).
August 31, 2020
Health technology tssessments play an important role in building confidence for use of biosimilars, yet very few meet criteria for thoroughness.
